ATE222489T1 - Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren - Google Patents

Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren

Info

Publication number
ATE222489T1
ATE222489T1 AT98955056T AT98955056T ATE222489T1 AT E222489 T1 ATE222489 T1 AT E222489T1 AT 98955056 T AT98955056 T AT 98955056T AT 98955056 T AT98955056 T AT 98955056T AT E222489 T1 ATE222489 T1 AT E222489T1
Authority
AT
Austria
Prior art keywords
thyroxine
malignant tumors
ketone
treatment
significant hormonal
Prior art date
Application number
AT98955056T
Other languages
English (en)
Inventor
Ernest Kun
Jerome Mendeleyev
Kalman G Buki
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octamer Inc filed Critical Octamer Inc
Application granted granted Critical
Publication of ATE222489T1 publication Critical patent/ATE222489T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT98955056T 1997-10-23 1998-10-23 Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren ATE222489T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/956,711 US5922775A (en) 1997-10-23 1997-10-23 Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
PCT/US1998/022383 WO1999020263A1 (en) 1997-10-23 1998-10-23 Thyroxine analogues having no significant hormonal activity to treat malignant tumors

Publications (1)

Publication Number Publication Date
ATE222489T1 true ATE222489T1 (de) 2002-09-15

Family

ID=25498590

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955056T ATE222489T1 (de) 1997-10-23 1998-10-23 Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren

Country Status (7)

Country Link
US (1) US5922775A (de)
EP (1) EP1024800B1 (de)
AT (1) ATE222489T1 (de)
AU (1) AU1195499A (de)
DE (1) DE69807349T2 (de)
ES (1) ES2181298T3 (de)
WO (1) WO1999020263A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
WO1999048495A1 (en) * 1998-03-25 1999-09-30 Biosource Technologies, Inc. Benzoates derivatives for inhibiting angiogenesis
US6326402B1 (en) * 1998-08-12 2001-12-04 Octamer, Inc. Methods for treating viral infections using a compound capable of inhibiting microtubules
US6677473B1 (en) 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
EP2428516A1 (de) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Neue Phosphor enthaltende Thyromimetika
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US7994222B2 (en) * 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
EP2250282A4 (de) * 2008-02-04 2011-05-18 Bipar Sciences Inc Verfahren zur diagnose und behandlung von parp-vermittelten krankheiten
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
KR20190107656A (ko) 2016-11-02 2019-09-20 이뮤노젠 아이엔씨 항체-약물 콘주게이트 및 parp 억제제로 병용 치료
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
KR20190126074A (ko) * 2017-02-03 2019-11-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 레티쿨론 4를 억제하기 위한 조성물 및 방법
EP3634426A4 (de) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. Zusammensetzungen zur behandlung von fibrose
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF TREATING GLIOBLASTOMA
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF
WO2020039094A1 (en) * 2018-08-24 2020-02-27 Xeniopro GmbH Phenoxy(hetero)aryl ethers of antiproliferative activity
JP2021518403A (ja) 2018-03-22 2021-08-02 バイキング・セラピューティクス・インコーポレイテッド 化合物の結晶形態及び化合物の結晶形態を生成する方法
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB642159A (en) * 1947-10-23 1950-08-30 Glaxo Lab Ltd Improvements in or relating to the preparation of diphenyl ethers
GB643089A (en) * 1947-10-23 1950-09-15 Glaxo Lab Ltd Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
GB9211415D0 (en) * 1992-05-29 1992-07-15 Ici Plc Process for the production of purified terephthalic acid
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
ES2181298T3 (es) 2003-02-16
DE69807349D1 (de) 2002-09-26
US5922775A (en) 1999-07-13
WO1999020263A1 (en) 1999-04-29
EP1024800A1 (de) 2000-08-09
DE69807349T2 (de) 2003-01-02
EP1024800B1 (de) 2002-08-21
AU1195499A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
ATE222489T1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
ATE300292T1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69127175T2 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE69839586D1 (de) Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE249233T1 (de) Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen
NO994330L (no) Metode for behandling av en tumor
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
NO932101L (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
ATE336282T1 (de) Katheter zur behandlung von prostaterkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1024800

Country of ref document: EP